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fibroblasts (CAF). CAF are important determinants of cancer invasiveness.
We have recently shown that CAF are recruited through a Platelet-derived
Growth Factor (PDGF)-D-mediated paracrine mechanism originating from
CCA cells. Herein, we aimed to understand the downstream effectors of
PDGF-D signaling and the cellular mechanisms by which PDGF-D promotes
the recruitment of CAF.
Methods: In human fibroblasts isolated from liver explants, we evaluated the
in vitro effects of increasing doses of rhPDGF-D (0.1, 1, 10, 100 ng/ml) on: a)
cell proliferation (MTS), b) cell migration (Boyden chambers), c) ERK1/2 ex-
pression (Western blotting), d) small GTPase (RhoA, Rac1, Cdc42) activities
(G-LISA), before/after treatment with Imatinib (1μM), a PDGFRβ antagonist.
Fibroblast migration induced by rhPDGF-D 100 ng/ml was also evaluated
after selective inhibition of RhoA (Y-27632, 10 μM), Rac1 (NSC23766, 75
nM) and Cdc42 (CASIN, 5 μM).
Results: Administration of rhPDGF-D significantly stimulated fibroblast pro-
liferation only at high doses (10 ng/ml, 100 ng/ml). In contrast, rhPDGF-D
induced a strong dose-dependent stimulation of fibroblast migration, start-
ing at 0.1 ng/ml and increasing by nearly ×10 the controls at 100 ng/ml
(p<0.0001). Both effects were inhibited by Imatinib. Similarly to fibroblast
proliferation, PDGF-D induced a significant increase of p-ERK1/2 only at
the highest doses. Conversely, PDGF-D induced a clear dose-dependent,
Imatinib-inhibitable, linear increase for Rac1 and Cdc42 activities. RhoA was
activated only at the highest doses. All chemical inhibitors of Rho GTPases
induced a significant reduction in fibroblast migration (35% for Cdc42, 60%
for Rac1, p<0.001), that was completely abrogated by the combined treatment
(Y-27632+NSC23766+CASIN).
Conclusions: PDGF-D secreted by CCA cells, stimulates PDGFRβ expressed
by fibroblasts, and by activating Rho GTPases (particularly Rac1 and Cdc42),
stimulates cell motility, resulting in CAF recruitment. Targeting PDGF-D-
mediated cross-talk between cancer cells and CAF at the level of PDGFRβ or
Rho GTPases may offer a novel therapeutic approach in CCA.
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Background: PBC is characterized by a long natural history and a low
incidence of cardiovascular events despite high cholesterol serum levels.
However, the role of metabolic conditions (obesity, hypertension, insulin
resistance) eventually associated to PBC has not been analyzed.
Aim: To assess the influence of metabolic syndrome (MS) on the response to
UDCA and the survival in PBC patients.
Methods: The historic database collection (1975–2011) was used. The mean
follow up was 123 months, (range 6–425 months). All patients were treated
with UDCA (15 mg/kg/day). Hypercholesterolemia was treated with statins or
fibrates when total cholesterol was >240 mg/dl. Responders to UDCA were
defined subjects who reached at least a 40% decrease in alkaline phosphatase
after 1 year. MS was defined MS according to the American Heart Association
criteria. Survival was analyzed with Kaplan-Meier curves.
Results: A total of 171 PBC patients were considered eligible for the study; 55
of them (32.1%) at presentation fulfilled the criteria for MS. LFTs and Mayo
score were comparable in patients with MS and in those without MS; only
GGT resulted significantly higher in the group with MS (243 vs. 159 IU/ml,
p=0.038). Histological stages and fibrosis score were similar in the two groups
at baseline. The occurrence of cardiovascular events during the follow-up was
significantly higher in patients with MS (p<0.01). The response to UDCA
was higher in the group without metabolic syndrome (p<0.05). Kaplan-Meier
curves were similar until a 200 month interval, thereafter survival was worse
in the group with MS, but the difference was not statistically significant.
Conclusion: MS when associated to PBC should be carefully treated, due to
the risk of cardiovascular events and the reduced response to UDCA.
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Introduction: Non-alcoholic fatty liver disease may lead to hepatic fibrosis.
Dietary habits affect gut microbiota; while endotoxins produced by Gram–
bacteria stimulate hepatic fibrogenesis. However, the mechanisms involved
in the process of liver damage and the potential effect of microbiota is still
unknown.
Aim: To analyze whether microbiota composition and bacterial translocation
may interfere with liver fibrogenesis.
Material, methods, and results: Mice were treated with control (CTRL) or
high fat (HFD) diet for 1 month and subsequently subjected to either BDL (2
weeks) or i.p. CCl4 (3 weeks). Microbiota transplantation was obtained by oral
gavage of previously gut-sterilized mice by antibiotic cocktail (Neomycin,
Ampicillin, metronidazole, vancomycin). mRNA for collagen α1(I) and
αSMA, collagen deposition (Sirius Red), hydroxyproline content, were in-
creased in the HFD-BDL mice versus CTRL-BDL mice, while no differences
were observed between CTRL-CCl4 mice and HFD-CCl4 mice. Culture of
mesentheric lymphnodes showed higher density of infection in HFD-BDL
mice versus CTRL-BDL mice, suggesting higher bacterial translocation rate.
No evidence of bacterial translocation was observed in CCl4-treated mice.
HFD-BDL mice showed the highest reduction in occludin mRNA expression,
suggesting increased intestinal permeability. Pyrosequence analysis revealed
a condition of dysbiosis characterized by an increase of Gram– vs. Gram+
bacteria, a reduced ratio between Bacteroidetes and Firmicutes and, more
specifically, a dramatic increase of the Gram– proteobacteria in HFD-BDL
versus CTRL-BDL mice. Inflammasome expression was increased in fibrotic
liver, but significantly reduced in the gut. Furthermore, microbiota transplan-
tation revealed more liver damage in the chimeric mice treated with CTRL
diet but receiving the microbiota of HFD-treated mice.
Conclusions: By increasing the percentage of Gram– producing endotoxins,
different dietary habits lead to a pro-fibrogenic effect in the course of chronic
hepatic liver damage. Bacterial translocation, altered intestinal permeability
and dysbiosis are needed by hepatic steatosis to act as co-factors in chronic
liver diseases.
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Background: Both hepatic (HF) and visceral fat (VF) are involved in the
onset and progression of metabolic syndrome and NAFLD. However, their
relative role is still debated.
Aim: To determine the relative contribution of HF and VF to both metabolic
derangements and histological liver damage in NAFLD patients.
Methods: In 22 non-diabetic, non-dyslipidaemic patients with biopsy-proven
NAFLD we measured whole abdomen VF by MRI, fasting endogenous
glucose production (EGP) and lipolysis by tracer infusion, peripheral in-
sulin resistance (IR) as HOMA, Hepatic-IR (EGP*insulin) and Adipo-IR
(FFA*Insulin). Hepatic histology was scored according to Kleiner, HF was
assessed as percentage of liver fat.
Results: VF increased with BMI (r=0.54, p<0.004) and HF (r=0.43, p<0.03),
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whereas HF was not correlated with BMI. Only HF, but not VF, was associated
with circulating FFA levels (r=0.51, p<0.01), and Adipo-IR (r=0.41, p<0.05),
while no correlation was found between either LF% or VF with Hepatic-IR or
HOMA.
Patients with NAS score ≥4 (vs. NAS 0–3) had increased VF (3.9±0.7 vs.
2.8±0.4 kg), FFA concentrations (525±52 vs. 804±98 mmol/l), peripheral
IR (HOMA: 3.7±0.5 vs. 2.8±0.8), Hepatic-IR (169±23 vs. 124±32), and
Adipo-IR (13.2±2.5 vs. 6.3±1.8) (all p<0.05). Considering only balloning
and lobular inflammation in the NAS score, subjects with a composite score
>2 had an impaired lipolysis suppression.
Patients with fibrosis vs. those without fibrosis, had increased VF (3.9±0.6
vs. 2.7±0.7 kg, p<0.03), but not HF, and no differences were found in the
indexes of IR.
Conclusions: In NAFLD subjects, hepatic fat is associated with metabolic
derangements and IR, but Adipo-IR and visceral fat accumulation appear to
provide a major contribution to liver damage.
Funding from the FP7/2007-2013 under grant agreement n°Health-F2-2009-
241762, for the FLIP project.
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Introduction and aim: At present there is a lack of effective treatments and
noninvasive diagnostic markers for nonalcoholic steatohepatitis (NASH). We
have recently demonstrated that hepatocyte-derived microparticles (MPs) are
critical signals contributing to angiogenesis and liver damage in NASH (Presi-
dential Plenary, AASLD 2012). Here we tested the hypothesis that circulating
hepatocyte-MPs are novel targets for noninvasive NASH monitoring.
Methods: Male C57BL/6 mice were placed on Choline-Deficient L-Amino
Acid (CDAA) diet, Choline-Supplemented L-Amino Acid (CSAA) or regular-
diet (RD) for 4 and 20 weeks (early stage and established NASH, respectively).
Circulating MPs were isolated from platelet-free plasma, detected by flow
cytometry and extensively characterized by electron microscopy in liver tissue
and circulation, dynamic light scattering and by LC MS/MS proteomic anal-
ysis. Liver specimens were collected and used for histological, biochemical,
and molecular analysis of steatosis, inflammation, angiogenesis, fibrosis and
cell death.
Results: MPs circulating levels were significantly increased only in mice
with established NASH (20 wks CDAA diet: 304,400 MPs/mL vs. 20 wks
CSAA 34,300 MPs/mL vs. RD 2,000 MPs/mL, p<0.0052). The increase was
time-dependent and MPs blood levels strongly correlated with histological
features of liver damage, in particular with fibrosis, as determined by morpho-
logic quantification of Sirius Red staining (r=0.736; p<0.0002), and cell death
determined by TUNEL assay (r=0.804; p<0.0001). We next characterized the
antigenic composition of circulating MPs using a comprehensive proteomic
approach by LC-MS/MS analysis. A gene ontology analysis of the proteins
identified 26.5% plasma membrane proteins, 58.8% cytoplasmic proteins,
8.8% nuclear proteins and 5.9% extracellular proteins. Analysis of the molec-
ular function of these proteins demonstrated that 35.3% were enzymes, 41.2%
were cytoskeleton or vesiculation proteins, 2.9% nucleosome proteins and
5.9% ribonucleoproteins.
Conclusion: Our data identified circulating MPs with a unique antigenic
composition as potential novel biomarkers for noninvasive diagnosis of
NASH.
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Background and Aims: There is evidence that patients with non-alcoholic
fatty liver disease (NAFLD) are at high cardiovascular risk and that the
prevalence and the severity of NAFLD are also driven by genetic background.
In NAFLD patients we tested the association of carotid atherosclerosis with
clinical, genetic and histological factors.
Materials and Methods: We assessed anthropometric, metabolic and his-
tological data (Kleiner score) in 162 consecutive biopsy-proven NAFLD
patients. Intima-media thickness (IMT) and carotid plaques, defined as focal
thickening of >1.3 mm at the level of common carotid artery, were evaluated
using ultrasonography. IL28B rs12979860 C>T, PNPLA3 rs738409 C>G,
GCKR rs780094 C>T, LYPLAL1 rs12137855 C>T, and NCAN rs2228603
C>T single nucleotide polymorphisms were also assessed.
Results: Carotid plaques were found in 59 (36.4%) cases, and in particular, in
32% PNPLA3 CC/CG vs. 52.9% PNPLA3 GG patients (p=0.02). Multivariate
logistic regression analysis showed that older age (OR 1.102), female gender
(OR 2.476), type 2 diabetes (OR 4.061), and PNPLA3 GG genotype (OR
2.679) were independently linked to the presence of carotid plaques. In
patients aged <50 years, 8/77 cases with PNPLA3 CG/CG genotype (10.9%)
had carotid plaques, vs. 6/15 (40%) with PNPLA3 GG genotype (p=0.02). By
contrast, in patients ≥50 years the prevalence of carotid plaques was similar
in subjects with PNPLA3 CC/CG and GG genotype (33/55, 60% vs. 12/19,
63%; p=0.75). Similarly, PNPLA3 CC/CG cases aged <50 had a lower IMT
than PNPLA3 GG patients (0.75±0.17 vs. 0.85±0.25 mm; p=0.05), while this
difference was not observed in patients aged ≥50 (0.93±0.25 vs. 1.00±0.26
mm; p=0.32).
Conclusion: PNPLA3 GG genotype is associated with a high risk of early
carotid atherosclerosis in NAFLD.
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Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common
form of chronic liver disease worldwide, ranging from simple steatosis to
steatohepatitis which may progress to cirrhosis, and hepatocellular carcinoma.
However, the molecular mechanisms underlying NAFLD development have
not been completely characterized. Recently, the p53 tumor suppressor protein
has gained attention as a modulator of cellular metabolism, responding to
several stress conditions, but its role in the progression of NAFLD remains
poorly understood. We designed an in vitro model of NAFLD to analyze how
different forms of p53 may affect the metabolic stress response induced by
free fatty acid (FFAs) overloading.
Materials and methods: Three cell lines carrying different forms of p53:
HepG2 (p53 wt), Huh7.5.1 (mutated-p53) and Hep3B (p53 knockout), were
cultured for 14 h in a medium containing oleic and palmitic acid (molar
ratio 2:1, respectively) at a final concentration of 1 mM, the most abundant
FFAs in western diets. Intracellular lipid accumulation and cell viability
were assessed by AdipoRed and MTS assay, respectively. Gene and protein
expression profiles of p53 and lipid metabolism-related genes were evaluated
by qRT-PCR and Western blotting.
Results: In the three cell lines the FFA treatment was not cytotoxic and
